Number one and most reliable source for Real-Time Breaking News and analysis, FDA approvals, Clinical Trials and Biotech Catalysts
Navigate the high-growth biotech sector with real-time FDA action date (PDUFA date), Phase 3 trial readouts, M&A tracking, and expert analysis from industry veterans with 20+ years of experience.
7-Day Free Trial (No Credit Card Required)
Quick reference guide to all platform features:
| Feature | What You Get |
|---|---|
| News That Impact Biotech Stocks | Clinical trials, regulatory decisions, M&A, partnerships |
| Trending Stocks | Pre-market, regular session & after-hours winners/laggards |
| FDA Calendar | PDUFA dates & AdCom meeting schedules |
| Biotech Stocks Facing FDA Decisions | Drug pending regulatory approvals monthly |
| Biotech Stocks On The Move | Market movers & potential risers tracking |
| Clinical Trial Calendar | Quarterly roundup & trial data watchlist |
| Long-Term Investor | Story ideas with sustained growth potential |
| Make Or Break Stocks | Stocks with imminent regulatory/clinical catalysts |
| Upcoming Earnings | Biotech earnings calendar & preview |
| IPO Alert | Upcoming biotech IPO notifications |
| Upcoming Events | Conferences, data readouts & regulatory events |
| IPO Calendar | Complete list of companies going public |
| M&A Calendar | Deal milestones, terms & timelines tracking |
| COVID-19 Drugs | Coronavirus treatment & vaccine development tracker |
Capitalize from RTT's 20+ years of expertise
The biotech sector offers unparalleled opportunities for substantial returns, with stocks routinely moving 50–300% on positive clinical trial results or FDA approvals. However, timing is everything. Therefore, we at RTT Biotech Investor ensure you stay ahead of key clinical and regulatory catalysts. Missing a PDUFA date or Phase 3 data readout can mean the difference between capturing significant gains or watching from the sidelines.
Subscribers benefit from our team's more than two decades of experience covering the biotech and pharmaceutical industry. Our analysts follow these companies and closely monitor developments helping you to be the first to identify stocks with strong fundamentals while keeping you abreast of all critical events.
The only platform to identify critical biotech catalysts and opportunities.
The only source for breaking news alerts.
Stay ahead of market-moving developments with our comprehensive news coverage. We track clinical trial results, regulatory decisions, mergers and acquisitions, partnership announcements, and corporate updates from healthcare companies listed on NASDAQ and NYSE. Get the information you need to make informed decisions before the market reacts.
There is a reason RTT has been number one on Google for more than a decade. FDA action date (PDUFA date), FDA Advisory Committee (AdCom) meetings, are critical "make or break" catalysts for biotech stocks. Our FDA Calendar provides comprehensive tracking of upcoming regulatory decision dates across large-cap, mid-cap, and small-cap biotech companies, helping you anticipate binary events that can dramatically move stock prices.
Clinical trials are binary speculative events that can make or break biotech stocks. Our Clinical Trial Calendar features a Quarterly Trial Data Roundup and curated Trial Data Watchlist, tracking Phase 1, Phase 2, and Phase 3 study results. Know exactly when critical data readouts are expected to limit risk and maximize profit potential.
Identify the day's biggest winners and laggards across all trading sessions. Our Trending Stocks section captures significant price movements in pre-market trading, regular market hours, and after-hours sessions—giving you a complete picture of biotech stock momentum throughout the trading day.
Major events or announcements made overnight, before market open, or during regular trading can trigger significant stock movements. Sometimes, substantial price action occurs on no apparent news. Our experienced analysts help you identify stocks, opportunities and gauge stock direction that others may have missed.
Focus on the highest-impact opportunities with our curated list of stocks facing imminent regulatory decisions or clinical trial catalysts. These binary events can result in dramatic price movements. Our Make Or Break section helps you identify and prepare for these pivotal moments.
Get a quick preview of biotech companies' scheduled earnings announcements. Quarterly reports often include pipeline updates, cash runway information, and forward guidance that can move stock prices. Stay prepared with our comprehensive earnings calendar covering the biotech and pharmaceutical sector.
Be first to know about upcoming biotech initial public offerings. Our IPO Alert service notifies you of newly filed and scheduled biotech IPOs, giving you time to research emerging companies before they begin trading. Early awareness of IPO opportunities can provide significant first-mover advantages.
Access our comprehensive list of biotech and pharmaceutical companies going public. The IPO Calendar helps you track potential investment opportunities from initial filing through pricing and trading debut. Monitor deal terms, pricing ranges, and expected listing dates for all healthcare sector IPOs.
Track key milestones, deal terms, and timelines of M&A activities in the biotech space. With large pharma facing a $300 billion patent cliff, acquisition activity is surging. Our M&A Calendar monitors announced deals, regulatory approval timelines, expected closing dates, and identifies potential acquisition targets based on pipeline strength and strategic fit.
Healthcare conferences and scientific meetings are major stock-moving catalysts. Track investor conferences like J.P. Morgan Healthcare Conference, Goldman Sachs Healthcare Symposium, and Morgan Stanley Global Healthcare Conference, plus medical society meetings including ASCO, ASH, AACR, and ESMO where companies present clinical data and strategic updates.
Monitor companies racing to develop treatments and vaccines for COVID-19 and its variants. This dedicated section tracks clinical trial progress, regulatory submissions, and approval decisions for coronavirus therapeutics—keeping you informed on this evolving area of drug development.
Our expert coverage spans the most promising therapeutic areas and investment themes:
ADCs, CAR-T cell therapy, checkpoint inhibitors, targeted protein degradation
CRISPR gene editing, AAV vectors, ex vivo & in vivo therapies, RNA medicines
GLP-1 receptor agonists, next-gen weight loss drugs, NASH/MASH therapies
Generative AI, protein folding, computational biology, techbio platforms
Orphan drug exclusivity, genetic disease treatments, precision medicine
Alzheimer's disease-modifying drugs, depression, schizophrenia treatments
after your 7-Day FREE Trial ends.
7-Day Free Trial (No Credit Card Required)
Gain access to a comprehensive biotech intelligence platform built for serious investors seeking clarity around FDA decisions, clinical trial catalysts, and biotech market opportunities.
Important Disclosure: Our service provides educational content and timely information to support your investment research. We do not offer buy/sell recommendations, entry/exit signals, or target prices for any securities featured in our coverage.
Answers to common questions about Biotech Investor
All of the free and premium services offered on RTTNews.com are provided for information purposes only. None of the information or opinions expressed in any of our services should be construed as an offer or solicitation to buy or sell, or as an endorsement, recommendation of any securities, options, futures or funds. We are not investment advisors and we do not provide personalized advice. If you need personal advice, then you should seek the advice of a qualified investment advisor.
All our services are designed to help you save time with your investment research. RTTNews does not warrant the reliability or completeness or accuracy of the Content found in our Services or its usefulness for any particular purpose. You are responsible for your own investment decisions. RTTNews will not be liable for any direct, indirect, incidental or any other type of loss or damages caused by a reader's reliance on information obtained on our site.
Please read our Terms and Conditions of service for complete terms.
